Please find attached the Unaudited Financial Results for the 2nd quarter and half year ended 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.7 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Revenue from operations dropped sharply to Rs 725.22 lacs in Q2 FY26 (down ~45% from Rs 1,310.84 lacs in Q2 FY25) and to Rs 1,666.89 lacs for H1 FY26 (down ~31% from Rs 2,403.98 lacs in H1 FY25). Despite weak top-line, H1 profit after tax rose to Rs 74.79 lacs (from Rs 33.63 lacs in H1 FY25), helped largely by a one-time gain of Rs 816.05 lacs from sale of investment property and fixed assets, reflected in the unusually high 'other income' of Rs 869.74 lacs. The company fully repaid its long-term borrowings of Rs 2,500 lacs during the period, reducing total assets to Rs 6,037.91 lacs from Rs 7,236.88 lacs. Net cash from operations was positive at Rs 1,548.37 lacs and cash balance improved to Rs 359.98 lacs. EPS for H1 stood at Rs 0.08. Auditor B Chakravarti & Associates issued an unqualified limited review report.
Core business revenue is shrinking meaningfully, but reported profit growth is largely driven by a one-time asset-sale gain rather than operations. Net debt reduction and healthy operating cash flow are positive for the balance sheet, but watch for sustained revenue recovery in upcoming quarters.